久久国产精品午夜一区_91精品國產高清久久久久久91_?级毛片免费全部播放_欧美色图在线视频一区二区三区_国产综合亚洲一区二区三区_中文字幕熟女网_国产精品男人爽免费视频_九九无码网战_亚洲日本三级电影在线观看_欧美日韩DVD手机在线不卡

This guidance is developed for immediate release (IR) dosage forms and is intended to provide  (1) general recommendations for dissolution testing; (2) approaches for setting dissolution specifications related to the biopharmaceutic characteristics of the drug substance; (3) statistical methods for comparing dissolution profiles; and (4) a process to help determine when dissolution testing is sufficient to grant a waiver for an in vivo bioequivalence study. This document also provides recommendations for dissolution tests to help ensure continuous drug product quality and performance after certain postapproval manufacturing changes. Summary information on dissolution methodology, apparatus, and operating conditions for dissolution testing of IR products is provided in summary form in Appendix A. This guidance is intended to complement the SUPAC - IR guidance for industry: Immediate Release Solid Oral Dosage Forms: Scale-up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation, with specific reference to the generation of dissolution profiles for comparative purposes.